


Supplementary Fig. S1. Remission rates. Remission (BVAS=0, GC <10mg/d prednisolone) rates at any time during the 24-months observation (A) and at 6, 12, 18 and 24 months (B). Complete remission (BVAS=0, GC = 0mg/d prednisolone) rates at any time during the 24-months observation (C) and at 6, 12, 18 and 24 months (D).



Supplementary Fig. S2. Kaplan-Meier survival analysis showing relapse-free survival over 24 months observation period in AAV patients with active renal disease. AAV: ANCA-associated vasculitis; RTX: rituximab; RTX/CYC: combination rituximab and cyclophosphamide.

Supplementary Fig. S3. Kaplan-Meier survival analysis showing relapse-free survival over 24 months observation period in AAV patients with active renal disease and an eGFR below 30ml/min. AAV: ANCA-associated vasculitis; GPA: granulomatosis with polyangiitis; RTX: rituximab; RTX/CYC: combination rituximab and cyclophosphamide; eGFR: glomerular filtration rate (MDRD-formula).

